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Abstract
In sickle cell disease (SCD), sickle hemoglobin (HbS) polymerizes upon deoxygenation,
resulting in sickling of red blood cells (RBCs). These sickled RBCs have strongly reduced
deformability, leading to vaso-occlusive crises and chronic hemolytic anemia. To date,
there are no reliable laboratory parameters or assays capable of predicting disease severity
or monitoring treatment effects. We here report on the oxygenscan, a newly developed
method tomeasure RBC deformability (expressed as Elongation Index - EI) as a function of
pO2. Upon a standardized, 22 minute, automated cycle of deoxygenation (pO2 median
16 mmHg ± 0.17) and reoxygenation, a number of clinically relevant parameters are pro-
duced in a highly reproducible manner (coefficients of variation <5%). In particular, physio-
logical modulators of oxygen affinity, such as, pH and 2,3-diphosphoglycerate showed a
significant correlation (respectively R = ‑0.993 and R = 0.980) with Point of Sickling
(PoS5%), which is defined as the pO2 where a 5% decrease in EI is observed during deoxy-
genation. Furthermore, in vitro treatment with antisickling agents, including GBT440,
which alter the oxygen affinity of hemoglobin, caused a reproducible left-shift of the PoS,
indicating improved deformability at lower oxygen tensions. When RBCs from 21 SCD
patients were analyzed, we observed a significantly higher PoS in untreated homozygous
SCD patients compared to treated patients and other genotypes. We conclude that the
oxygenscan is a state-of-the-art technique that allows for rapid analysis of sickling behav-
ior in SCD patients. The method is promising for personalized treatment, development of
new treatment strategies and could have potential in prediction of complications.
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1 | INTRODUCTION
In sickle cell disease (SCD) a single point mutation in the gene encoding
for β-globin chain underlies the production of the abnormal hemoglobin
S (HbS). HbS polymerizes upon deoxygenation which results in the
formation of hemoglobin polymers and eventually gives the red blood
cell (RBC) its characteristic sickled shape. Exacerbating the hypoxia-
induced polymerization is the inherent low-affinity of HbS, presumably
due to high levels of 2,3-diphosphoglycerate (2,3-DPG) present in
sickle RBCs.1 These sickled RBCs have strongly reduced deformability
and show increased adherence to vascular endothelium, leading to vaso-
occlusive crises.2–4 Hydroxyurea (HU), regular blood transfusion, and
L-glutamine are the main treatment options in SCD, with allogeneic
hematopoietic stem cell transplantation being the only curative therapy
currently available.5 Remarkably, clinical severity varies considerably
despite the fact that all SCD patients carry the same homozygous point
mutation in the β-globin gene. To date there is no reliable laboratory or
clinical parameter available to predict severity and/or complications.
An individual patient's tendency to “sickle” can be tested in vitro
using a so-called sickling assay: RBCs are incubated under hypoxic
conditions and manually or digitally counted using a light microscope.
This assay is still widely applied in research, and many preclinical and
early phase pharmacologic and gene therapy trials use this assay as
outcome variable to predict clinical effect.6–11 However, there are
many disadvantages: It is time consuming, it has low sensitivity and
high variability, and the process is not automated. More importantly,
morphological characteristics of sickle cells may not correlate well
with physiologic characteristics, such as deformability.12
RBC deformability at normoxic conditions is compromised in patients
with SCD due to irreversibly sickled cells, as well as altered hydration
causing a decrease in surface/volume ratio.12–14 Osmotic gradient ekta-
cytometry, in which deformability is measured as a function of a continu-
ous change in osmolarity, is a well-established method, in particular in
hereditary disorders of the red cell membrane.15–18 In SCD, osmotic
gradient ektacytometry showed that increasing HbF induces a better
surface-to-volume ratio thereby improving deformability in untransfused
patients with SCD.19 RBC deformability during normoxic conditions as a
marker for complications has also been investigated in the past, and a
negative correlationwas found between an increase in RBC deformability
and osteonecrosis or painful sickle cell crises.20–22 In contrast to these
findings, RBC deformability was found to be decreased during an acute
vaso-occlusive crises when compared to steady state values.23 Thus, in
itself, RBC deformability during normoxic conditions gives inconsistent
resultswhichmakes it unsuitable to be used as predictive biomarker.
Therefore, an assay that investigates sickling during deoxygenation
is required to monitor treatment and disease state in patients with SCD.
Importantly, this assay could identify individuals who are at increased risk
for certain complications, and potentially predict response to therapy.
Finally, it contributes to a better understanding of the clinical effect of
new antisickling agents. In this study, we evaluate the oxygenscan, which
investigates RBC deformability as a function of continuously changing
pO2, allowing us to characterize individual sickling behavior in SCD
patients.
2 | METHODS
2.1 | Blood specimens
University Medical Center Utrecht (UMCU): Whole blood of patients
with SCD who were included in 2 different clinical studies (Netherlands
Trial Register [NTR] identifier, NTR 6779 and NTR 6462) was used.
Additional samples were collected from discarded anonymized EDTA
blood of patients with SCD who visited outpatient clinic. Whole blood
from healthy controls was collected through the Mini Donor Service,
which is approved by the ethical committee of the UMCU and in accor-
dance to the declaration of Helsinki.
The Children's Hospital of Philadelphia (CHOP): Leftover EDTA
blood samples from individuals with SCD after routine clinical visits were
utilized for the traditional antisickling studies. The use of such samples,
with informed consent, is in accordance to an approved IRB protocol.
2.2 | Oxygen gradient ektacytometry: the
oxygenscan
The Laser Optical Rotational RedCell Analyzer (Lorrca, RRMechatronics,
Zwaag, The Netherlands) is a next generation ektacytometer that mea-
sures different qualitative aspects of RBC deformability expressed as
Elongation Index (EI). The pO2scan is a new add-on of the Lorrca, allow-
ing the measurement of red cell deformability as a function of a continu-
ously changing gradient of O2 tension. In brief, a couette system is used
to apply shear stress on the RBCs, which are diluted in a viscous solution
(Iso Oxy), consisting of polyvinylpyrrolidone (PVP) with characteristics of
whole blood (ie, osmolarity and pH). Between a static cylinder (bob) and
rotating cylinder (cup), there is a small gap in which the blood suspension
is injected (Figure 1A). Light from the laser beam is scattered by the pres-
ence of RBCs and this diffraction pattern is projected and analyzed. In
healthy controls, the diffraction pattern is circular at rest and elliptical
shaped at higher shear stress (Figure 1B).15
To carry out the oxygenscan, 50μL of whole blood, standardized to a
fixed RBC count of 200 × 106 is suspended into 5 mL Iso Oxy (osmolar-
ity 282-286 mOsm/kg, pH 7.35-7.45) at room temperature (± 22°C).
Approximately 2mL of the sample solution is slowly injected into the gap
between the cup and bob until a fixed level is attained (Figure 1C). The
bob is maintained at a constant temperature of 37°C. Inlet of nitrogen
gas from above facilitates deoxygenation (Figure 1C). O2 tension is mea-
sured every 20 seconds by means of a small oxygen (O2)-spot which is
covered with luminophore that is present in the wall of the cup. The pO2
is calculated from the amount of quenching of the signal that is sent from
the fiber to the O2-spot. One oxygenscan consists of approximately
80 measurements of EI, during one round of deoxygenation (1300 sec-
onds), and followed by reoxygenation (280 seconds). Shear stress is fixed
at 30 Pa. Ambient air pO2 in the cup was about 160 mmHg and is gradu-
ally lowered to below 20 mmHg (2.7 kPa, 2,9%) O2. Reoxygenation
occurs due to passive diffusion of ambient air.
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2.3 | Oxygenscan parameters
When considering a typical oxygenscan curve (Figure 1F), 6 parameters
are considered to reflect various features of the process of HbS polymeri-
zation or sickling: EImax: maximum EI before deoxygenation that repre-
sents baseline position and shows overall deformability of the total RBC
population. EImin: minimumEI, representingminimal deformability result-
ing from changes in shape and orientation of (sickle) RBCs upon deoxy-
genation (Figure 1D). DeltaEI: difference between EImax and EImin,
indicating sickling capacity during one round of deoxygenation. Point of
Sickling5% (PoS5%): pO2 (mmHg) at which 5% decrease of EImax during
deoxygenation is observed. This indicates the pO2 where sickling starts.
Area: area under the curve which is defined by an integral calculation of
the EI and pO2 measurements between minimum pO2 and 100 mmHg.
This is the result of EImax, EImin, and PoS. Recovery: percentage of EI
after reoxygenation compared to EI just before deoxygenation measured
at the pO2 between 100 and 120 mmHg. This represents the capacity of
sickled cells to unsickle during reoxygenation.
2.4 | Digital microscopy
Smears of peripheral blood of patients were analyzed using the CellaVi-
sion digital microscope DM96 (software 5.0.1build11), the traditional
neural network of which classifies sickle cells based on manually de-
signed features, such as shape, color, and texture features. Sickle cell
counts were expressed as percentage of absolute cell count analyzed by
digital microscopy.24
F IGURE 1 Experimental setup of the
Lorrca with the oxygenscan module and
representative oxygenscan curve.
(A) Experimental setup of the Lorrca. (B)
The diffraction pattern of healthy RBCs is
elliptical when shear stress of 30 Pa is
applied. (C) Schematic graph of the
oxygenscan add-on which shows
deoxygenation with nitrogen gas (N2), the
O2-spot and LED-fiber, a device to measure
oxygen tension. (D) Upon deoxygenation
and shear stress (30 Pa) the diffraction
pattern changes from an ellipse to a
rhomboid shape. (E) Sickle RBCs fixated
after a similar round of deoxygenation
show change in shape, control sickle RBCs,
without nitrogen gas, show no change in
shape. (F) A representative curve of the
oxygenscan. Maximum Elongation Index
(EImax) represents baseline position, and
shows overall deformability of the total
RBC population. Minimum EI (EImin)
represents minimal deformability which is
caused by change in shape and orientation
of RBCs upon deoxygenation. DeltaEI
(difference in EI between EImax and EImin)
shows how many cells can sickle during
one round of deoxygenation. Point of
sickling (PoS5%, pO2 at 5% EI decrease)
embodies the oxygen tension when the
first RBCs start to sickle. The area under
the curve (from minimum pO2-100 mmHg)
is calculated in the parameter Area and this
summarizes EImax, EImin, and PoS. The
capacity of sickled cells to unsickle during
reoxygenation is represented in the
parameter Recovery (percentage of EImax
reached during reoxygenation). To aid
interpretation, we connected all data points
in every individual experiment by a line in
the graphical presentation of the results
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2.5 | In vitro addition of HbAA blood to HbSS blood,
mimicking red cell transfusions
To investigate the effect of adding RBCs of healthy donors, ABO and
rhesus matched RBCs of a healthy donor was mixed with whole blood
of a patient with SCD to reach the following percentages of HbS
blood: 100%, 75%, 50%, 25%, and 0%.
2.6 | Influence of 2,3-DPG levels, pH, and
temperature
To assess the influence of 2,3-DPG levels on oxygenscan parameters,
complete blood count and oxygenscans were performed within 10
minutes after blood collection, and after 24 hours. Whole blood was
kept either at 4°C, room temperature (± 22°C) and 37°C for 24 hours.
2,3-DPG was measured by spectrophotometry (SpectraMax M2e,
Molecular Devices, Sunnyvale, CA) using the 2,3-DPG assay kit (Roche).
2,3-DPG levels were normalized to hemoglobin levels.
To assess the influence of temperature, oxygenscans were carried
out with bob temperatures of 35, 37, 39, 41, and 43°C.
To investigate the influence of pH, the pH of the Iso Oxy was set
to 6.9, 7.1, 7.3, 7.7, and 7.9 before being used in the oxygenscan.
2.7 | In vitro incubation with antisickling agents
GBT440, 5-PMFC, and INN312
GBT440, 5-PMFC, and INN312 are a class of antisickling aromatic alde-
hyde agents that modulate hemoglobin oxygen affinity by stabilizing
the higher oxygen affinity relaxed state (R-state) of hemoglobin and/or
destabilizing the low oxygen affinity tense state (T-state) of hemoglobin.
GBT440 (2-hydroxy-6 ((2-(1-isopropyl-1H-pyrazol-5-yl) pyridin-3-yl)-
methoxy) benzaldehyde, MedChemExpress, Sollentuna, Sweden) is a
novel, orally bioavailable agent currently in clinical trials for SCD.9,25
5-PMFC (5-[Phenoxymethyl]-2-furan carbaldehyde) is an aryl ether
derivative of 5-(hydroxymethyl)furfural (5-HMF), with a potent antisick-
ling effect.10 Designated International Nonproprietary Name-312
(INN312) is a designed and synthesized derivate of vanillin.8,26
Whole blood (20% hematocrit) was added to N-[Tris(hydroxy-
methyl)methyl]-2-aminoethanesulfonic acid (TES)-buffer (pH 7,4),
which contained 30 mM TES-sodium salt and 30 mM TES-free acid
(both Merck KGaA, Darmstadt, Germany), supplemented with
130 mM NaCl, 5 mM KCl, 10 mM glucose, and 0.2% bovine serum
albumin. These suspensions were incubated with the agents for 1 hour
at 37°C at normoxia. Concentrations used for incubation were 1 mM
and 2 mM of GBT440, and 1 and 5 mM of 5-PMFC and INN-312.7,10
Antisickling agents were dissolved in dimethyl sulfoxide (DMSO),
while incubation with DMSO alone was used as a negative control.
2.8 | Morphological analysis after in vitro incubation
with antisickling agents
To compare the outcome of the effect of the agents mentioned earlier,
sickling was also measured using previously reported methodology with
slight modifications.7,10,27 Briefly, whole blood was suspended (20%
hematocrit) in isotonic Hemox buffer (TCS Scientific Corp), pH 7.4, sup-
plemented with 10 mM glucose and 0.2% bovine serum albumin and
incubated at normoxia in varying concentrations of GBT440 (1, 2 and
5 mM), 5-PMFC (1 and 5 mM), and INN312 (1 and 5 mM) at 37°C for
1 hour. Next, suspensions were incubated under hypoxic condition
(2.5% Oxygen gas/97.5% Nitrogen gas) at 37°C for 1 hour. Cells were
fixed and analyzed by lightmicroscopy.
2.9 | Statistical analysis
Experiments were mainly carried out in duplicates, mean, SD, and coeffi-
cient of variation (CV) were calculated. Statistical analysis was performed
using IBM Statistics SPSS (v21) and Graphpad Prism. One-way ANOVA
(post-hoc Tukey's test or Dunnett's test) or a Kruskal-Wallis test (post-hoc
Dunn's test) was used when appropriate. We normalized results in the
experiments with 2,3-DPG because of known individual differences in
2,3-DPG levels. Results of incubation with antisickling agents was normal-
ized to enable the comparison of DeltaEI at 18 mmHg with the classical,
microscopy-based sickling assay. Pearson's correlation was used to deter-
mine correlations of oxygenscan parameters with laboratory and clinical
parameters. A P-value of <0.05was considered statistical significant.
3 | RESULTS
3.1 | The oxygenscan reproducibly characterizes red
blood cell sickling
To validate the technique whole blood samples of 21 individuals with
SCD, 5 individuals with sickle cell trait, and 8 healthy donors were used.
A representative oxygenscan and its derived parameters is shown in
Figure 1F. Importantly, parameters from duplicate measurements gen-
erally had a CV <5% (median 1.83%). In case a CV >5% was obtained, a
third measurement was performed. The parameters EImax and Recov-
ery appeared to be the most robust with median CVs <1%.
Measurements of pO2 and EI are not performed at the same posi-
tion in the cup. This ensures a better discrimination between the
deoxygenation and reoxygenation curves and, hence, a better inter-
pretation of them.
In order to confirm that the change in diffraction pattern during
deoxygenation reflects sickling, cells were deoxygenated outside the
Lorrca, under comparable conditions, fixed and analyzed by light micros-
copy as described. Compared to oxygenated conditions sickling is clearly
induced upon deoxygenation (Figure 1E and Supporting Information).
Upon storage of whole blood at 4°C oxygenscan curves shifted
slightly upward. When stored for 24 hours at 4°C curves remained sta-
ble, with minor increases in EImax (1.7%), PoS (2,7%), DeltaEI (9.2%), and
Area (6.7%). Minor decreases of 6.7% in EImin and 0.6% in Recovery
were observed under these conditions. Upon longer storage, oxygen-
scans shifted upward. (Supporting Information Table S1).
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3.2 | The oxygenscan can adequately assess the
effect of blood transfusion
In order to investigate the direct effects of blood transfusions on sickling
behavior, RBCs of a healthy control (HC) was mixed with whole blood of
a SCD patient in different amounts (Supporting Information Figure S2A).
Supporting Information Figure S2B and S2G shows that EImax and EImin
shifted toward normal upon increasing percentages of HbAA blood. At
the same time the PoS shifted to the left (Supporting Information
Figure S2D), whereas DeltaEI decreased and Area increased (Supporting
Information Figure S2C and S2E). Recovery also increased to 100%
(Supporting Information Figure S2F).
All oxygenscan parameters correlated significantly with the percent-
age of whole blood. EImin showed a striking linear correlate of r = 0.998,
P < 0.0001 (pooled data of 3 patients, individual correlations were above
r = 0.987 and P < 0.01, Supporting Information Figure S2G-L).
3.3 | Oxygenscan parameters reflect the influence of
physiologic modulators of the Hb-dissociation curve
Temperature, pH and 2,3-DPG are important cellular modulators of the
O2 affinity of hemoglobin and thereby of sickling. These parameters are
therefore expected to exert effect on the oxygenscan. Oxygenscans and
2,3-DPG were essentially unchanged after 24 hours at 4°C (Supporting
Information Figure S2A-G). When kept at room temperature or 37°C,
2,3-DPG had decreased after 24 hours (normalized and pooled data are
shown in Supporting Information Figure S2B). 2,3-DPG showed a strong
correlation with PoS (r = 0.980, P = 0.020, Supporting Information
Figure S2F and S2K) and EImin (Supporting Information Figure S2D
and S2I).
Upon lowering the pH of Iso Oxy, an increase of EImax, DeltaEI,
and PoS was observed, and EImin, Area, and Recovery decreased
(Supporting Information Figure S3A-G). Upon increasing the pH, the
opposite effect was observed (Supporting Information Figure S3A-G).
PoS appeared to correlate best with pH change (r = −0.993, P < 0.001
(pooled data, Supporting Information Figure S3K), indicating that lower-
ing pH results in sickling that starts at higher pO2.
Next,we performed series of oxygenscans of a single sample at differ-
ent cup and bob temperatures. Results were similar as those found with
pH adjustments (Supporting Information Figure S4). EImax decreased
upon increased temperature and correlated best (linear correlate
r = 0.996, P < 0.001), indicatingRBC deformability at normoxic conditions
is temperature dependent (Supporting Information Figure S4G).
3.4 | The oxygenscan provides a means to evaluate
the efficacy of antisickling agents
Currently several new drugs for SCD are being tested in clinical trials.With
blood of 6 SCD patients we investigated 3 of those drugs (GBT440,
5-PMFC, and INN312) for their efficacy on directly preventing hypoxia-
induced sickling using the oxygenscan as readout. GBT440 showed a large
improvement in oxygenscan parameters at a concentration of 1 mM and
an even larger effect at 2 mM (Figure 2A). After incubation with GBT440,
EImax slightly decreased. In contrast, EImin increasedwith increasing doses
of GBT440, which was significant for 2 and 5 mM (P = 0.005 and 0.001,
Figure 2B). Similar to these findings, DeltaEI and PoS significantly improved
with increasing GBT440 concentration (P < 0.001, Figure 2C and D). Area
significantly improved as well (P < 0.001). The same pattern was observed
with 5-PMFC and INN312, with the latter showing the higher efficacy of
the two (Figure 2B-E). However, at dosages of 1 mM the effect of these
2 compounds was lower compared to GBT440 (Figure 2B-E): EImin
increased with 1 mM and significantly increased with 5 mM (P < 0.001),
DeltaEI decreased significantly with 5-PMFC 5 mM (P < 0.001) and
INN312 1 and 5 mM (P < 0.01). PoS decreased in both concentrations of
5-PMFC and INN312, with 5mMbeing significant in both (P< 0.001).
Importantly, when oxygenscan parameters were compared with the
conventional sickling assay (microscopy), the results showed similar pat-
terns and were correlated (r = 0.934 P = 0.002, Figure 2F and G). How-
ever at a lower concentration of GBT440, and to lesser extent also
5-PMFC and INN312, a slightly larger antisickling effect was observed
with the conventional sickling assay (Figure 2F).
3.5 | The oxygenscan is able to discriminate between
different genotypes and treatment regimens
In order to investigate if the oxygenscan can detect differences
between genotypes and treatment regimens, oxygenscans were per-
formed with whole blood of 21 individuals with SCD, 5 individuals
with HbS trait, and 5 healthy controls (HC). Homozygous patients
without treatment (HbSS untreated, n = 7) were compared to HbSS
patients treated with HU (n = 5), HbSS patients treated with exchange
transfusion (n = 3), HbS/βothalassemia (n = 1), HbSS patients with
α-thalassemia (n = 2), hemoglobin SC disease patients (HbSC, n = 3),
HbS traits (n = 5) and HC (n = 5). Representative curves of groups
with 3 or more patients are shown in Figure 3A-D, with the mean of
the different groups of EImax, EImin, PoS, and Recovery shown in
Figure 3E-H. Absolute values of all oxygenscan parameters are
reported in Supporting Information Table S2. A significant decrease of
PoS was seen in all groups compared to untreated HbSS patients,
except HbSS individuals who had been recently transfused. Recovery
was significantly lower in HbSC patients compared to all the other
groups. These results show that the oxygenscan is able to discriminate
between different genotypes and treatment regimens.
When levels of HbF and HbS of patients with HbSS, HbSβ0,
HbSS/α-thalassemia with/without HU, were correlated with oxygen-
scan parameters, EImin showed the strongest correlations (r = 0.833
and r = −0.852, both P < 0.001, Figure 4A-B and Supporting Informa-
tion Figure S5). Digital microscopy findings of these patients were also
correlated with oxygenscan parameters. EImax showed the strongest
correlation with sickled cells at normoxia (r = 0.596, P = 0.019,
Figure 4C).
RAB ET AL. 579
F IGURE 2 Effect of pharmacologic modulators of HbS polymerization on Oxygenscan parameters. Incubations were carried out with n = 3 in
case of 2 and 5 mM GBT440, n = 6 in other incubations). (A) Representative graph of effect of in vitro treatment of RBCs of patients with SCD
with GBT440 1 and 2 mM. (B) Normalized means of minimum Elongation Index (EImin) of RBCs incubated in absence or presence with different
concentrations of antisickling agents. (C) Normalized means of Point of Sickling (PoS). (D) Normalized means of DeltaEI (difference between
EImax and EImin) which represents sickling capacity. (E) Normalized means of DeltaEI at the specific pO2 tension of 18 mmHg (2.5% O2).
(F) Normalized sickling after incubation in absence or presence of antisickling agents, measured by microscopy, after deoxygenation at 18 mmHg
(2.5% O2). G, Linear correlation between Oxygenscan measured sickling by DeltaEI and microscopy. Error bar represents SD. ****P < 0.0001,
***P < 0.001, ** P < 0.01, *P < 0.05., ns, not significant. Dashed lines represent 95% confidence intervals
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4 | DISCUSSION
The oxygenscan is a rapid and reproducible technique, that is developed
to assess RBC sickling under automated continuous deoxygenation and
reoxygenation. We report for the first time on the potential of the oxy-
genscan tomonitor clinical conditions and parameters that influence HbS
polymerization. We found strikingly strong correlations of oxygenscan
parameters with physiological and pharmacological modulators of HbS
polymerization that are much stronger than in previously reported
assays.11 Importantly, diverse physiologic and pharmacologic conditions
correlated best with particular oxygenscan parameters. This underlines
the specificity of the various oxygenscan parameters: Conditionsmimick-
ing exchange blood transfusion were found to specifically affect EImin,
similarly to HbF and HbS levels (Figure 4A-B). Physiological modulators
F IGURE 3 Oxygenscan
parameters in relation to different
genotypes and treatment of patients
with SCD. (A) Representative graph
of RBCs of Hydroxyurea treated
homozygous SCD patients (HbSS
HU) in relation to untreated HbSS
patients. (B) Representative graph of
RBCs of HbSS patients treated with
blood transfusion (HbSS
transfusion). (C) Representative
graph of RBCs of patients with
Hemoglobin SC Disease (HbSC).
(D) Representative graph of RBCs of
HbS carriers (HbS trait) and healthy
controls. (E) Means of maximum
Elongation Index (EImax) in various
conditions mentioned earlier. (F)
Means of minimum EI (EImin) in
various conditions. (G) Means of
Point of Sickling (PoS, pO2 when
5% decrease in EI is reached) in
various conditions. (H) Means of
Recovery (% of start EI) in various
conditions. Error bar represents
SD. ****P < 0.0001, ***P < 0.001,
** P < 0.01, *P < 0.05., ns, not
significant
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of oxygen affinity predominantly affected PoS (Supporting Information
Figures S2 and S3). Regarding in vivo treatment of SCD, our findings show
that RBCs of untreatedHbSS patients start to sickle at higher oxygen ten-
sions. Treatment with either HU or transfusion lowers the PoS indicating
a lower pO2 at which cells start to sickle. In case of HbSC patients, Recov-
ery is significantly lower compared to the other groups indicating distinct
processes of unsickling.28 We speculate that this reduced capacity to
recover could be involved in the distinct vaso-occlusive phenotype of
HbSC patients.
4.1 | EImin is a reliable biomarker of the efficacy of
blood transfusion
Our results show a strong correlation of EImin with the distribution of
HbS, HbF, and HbA, and their effect on polymerization (Figure 2B, 3F,
and 4A-B). EImin shows the deformability at the point of minimal pO2
during an oxygenscan and reflects howmany cells are sickled. The physi-
ological ranges of intravascular pO2 tension differ between tissues and
blood vessel diameters, with the lowest values found in the bonemarrow
of live animals (ie, 17.7 mmHg).29,30 Oxygenscans curves reach at least
20 mmHg in >95% of measurements, with a mean of 15.9 mmHg (SEM
0.17). The minimal pO2 during the oxygenscan is yet another relevant
functional characteristic. In contrast to other sickling assays, in which a
nonphysiologically low pO2 is used, often during several hours. Other
assays use sodiummetabisulfite, which depletes RBCs fully from oxygen.
Both techniques result in full sickling of RBCs, even in sickle cell trait.
The fact that oxygenscans of individuals with sickle cell trait do not
show any significant sickling behavior compared to patients with SCD
underlines the physiological applicability of the oxygenscan (Figure 3A-D
and F).
EImin therefore is a potent parameter for assessing the direct
effects of blood transfusion and distribution of HbS, HbF, and HbA.
We suggest EImin is mostly predicted by the percentage of cells that
are not able to sickle at all and therefore is most influenced by blood
transfusion and F-cells.
4.2 | The potency of antisickling agents is captured
by DeltaEI
DeltaEI can be used as outcome parameter in the assessment of the effi-
cacy of new treatments that inhibit sickling. As shown by the experi-
ments mimicking blood transfusion (Supporting Information Figure S1),
DeltaEI reflects the percentage of RBCs that sickle upon deoxygenation
and as such is comparable with the conventional sickling assays (micros-
copy). In our experiments with the antisickling agents GBT440, 5-PMFC,
and INN312, data of the conventional assay were compared to DeltaEI
and a similar pattern was observed (Figure 2E-F). Overall, the effects
were more pronounced in the conventional assay, which could be due to
a longer exposure to hypoxic conditions in the latter. This results in a
higher amount of sickled cells at the start, and thus a more pronounced
F IGURE 4 Oxygenscan parameters are associated with HbF, HbS, and sickled cells at normoxia. (A) Linear correlation of minimum Elongation
Index (EImin) and HbF. (B) Linear correlation of EImin and %HbS. (C) Linear correlation of maximum EI (EImax) and % sickled cells at normoxia
measured with digital microscopy. (D) Representative curve of the effect of addition of 50% HBAA blood to 50% HbSS blood and a
representative curve of HbS trait. (E) Percentage HbS in the mixture of 50% HbSS blood with 50% HbAA blood (n = 2) and HbS trait (n = 5). (F)
DeltaEI in both groups mentioned earlier. Dashed lines represent 95% confidence intervals. Error bar represents SD
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effect of antisickling agents. Importantly, cells that sickle instantly do not
have the “sickle” shape but a more irregularly shaped or “star” shaped
appearance, also called “mosaic” cells.31 These cells have a different ori-
entation in the flow in the Lorrca than fully sickled RBCs and, hence,
behave differently in deformability measurements. Moreover, such cells
are regarded as sickled cells but they likely are still able to deform to a
certain extent. This could account for the less pronounced effect of anti-
sickling agents as determined by the oxygenscan.
DeltaEI has a strong correlation with percentage HbSS blood
(Supporting Information Figure S1J) and can distinguish between a
mixture of HbSS and HbAA RBCs and a population of HbAS RBCs
(HbS trait, Supporting Information Figure S1C, S3D and 4D-F). A fea-
ture that could be very helpful for upcoming gene-therapy trials in
which an assay is needed that discriminates between mixed chimerism
of fully corrected cells (50% HbAA and 50%HbSS) and fully engraft-
ment of half corrected (100% HbAS) cells. Therefore DeltaEI is an use-
ful parameter, in particular in the evaluation of individuals with HbS
trait and the development of new treatment strategies.
4.3 | PoS discriminates between genotypes and
different treatment regimens
We show that PoS correlates with 2,3-DPG levels and other modula-
tors that have an effect on the hemoglobin dissociation curve, such as
pH and temperature (Supporting Information Figure S2A, B, F, and J).
PoS is unique in its ability to determine the pO2 at which RBCs start
to sickle, and is therefore of high value in the development and clinical
testing of new drugs, in particular antisickling agents. When consider-
ing individuals with HbS trait, PoS has a distinct value in this group
compared to controls and SCD patients (Figure 3G). PoS also is the
most informative parameter when considering different treatment in
groups of SCD patients.
Based on these observations we conclude that PoS likely reflects
properties of an individual's hemoglobin dissociation curve.
4.4 | EImax reflects percentage of sickled cells at
normoxia and RBC hydration
In whole blood, the percentage of sickled cells at normoxia compared
to relatively healthy cells seems to have the most pronounced effect
on EImax. The number of sickled cells at normoxia correlated to EImax
(Figure 4C), indicating that already sickled cells lower the overall
deformability and thereby EImax. We suggest that EImax reflects the
percentage of nondeformable cells at ambient air, which are the dense
cells containing HbS polymer and sickled cells at normoxia.
4.5 | Comparison with other hypoxic deformability
assays
In the past several approaches to measure RBC deformability under
hypoxic conditions have been developed. All but one were based on a
deoxygenation step that took place outside the ektacytometer.32–35
In contrast to the oxygenscan, these approaches involved either a
deoxygenation or reoxygenation step, or used hypoxia and normoxia as
different conditions. A very recent study demonstrated a strong effect of
GBT440 on RBC deformability, but no pO2 could be determined and
related to the measurements.36 The oxygenscan allows now for the first
time the study of sickling behavior during both automated deoxygen-
ation and reoxygenation in a reproducible and fast manner.
One of the strengths of the oxygenscan is that deformability is
measured at a whole range of different oxygen tensions. Furthermore,
the technique has an excellent reproducibility, the time to perform an
oxygenscan measurement is relatively short and it takes only a small
amount of whole blood. More importantly, the oxygenscan is a func-
tional assay that determines various aspects of the sickling process,
each represented by different parameters.
A limitation of the technique is that measurements are performed on
the total RBC population. Therefore, individual differences in cellular
behavior or subpopulations of cells are not considered and, consequently,
outcome parameters always reflect the mean behavior of all cells. Also,
theminimal pO2 during deoxygenation does not reach 0mmHg. Although
this pO2 is not a physiologically relevant value, it would be of interest to
measure in order to see howmuch the EI would further decrease.
Our data show that apart from the influence of HbF, HbS, and HbA,
this assay also takes individual hemoglobin dissociation curves and per-
centage of sickled cells at normoxia into account. Therefore, the oxygen-
scan is an assay which simultaneously determines a number of clinically
important factors involved in SCD pathophysiology. As such it may rep-
resent a better alternative for the conventional sickling assay and fill the
clinical need for a reliable biomarker. Current studies are aimed at inves-
tigating the applicability of the oxygenscan in the determination of clini-
cal severity and vaso-occlusive crisis, as well as a more comprehensive
analysis of the effect of current and new treatment strategies.
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